A carregar...
Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II)
BACKGROUND: BAY 81-8973 is a new full-length human recombinant factor VIII product manufactured with technologies to improve consistency in glycosylation and expression to optimize clinical performance. OBJECTIVES: To demonstrate superiority of prophylaxis vs. on-demand therapy with BAY 81-8973 in p...
Na minha lista:
| Publicado no: | J Thromb Haemost |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley & Sons, Ltd
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4671268/ https://ncbi.nlm.nih.gov/pubmed/25546368 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jth.12828 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|